Latest Biotech News

Amgen is pushing back against the FDA as the agency weighs withdrawing Tavneos (avacopan), a rare vasculitis drug. According to the report, FDA concerns were raised in connection with securities...

Takeda’s zasocitinib (TAK-279) beat Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout for moderate to severe plaque psoriasis. The result moves...

Parabilis Medicines set a large biotech listing milestone, completing a $770.5 million IPO via the Nasdaq after underwriters exercised their overallotment option. The listing follows a streak of...

SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines into clinical development. The round was led by Vida Ventures and included...

Oricell moved its GPC3-targeted immune cell strategy into confirmatory development for liver cancer. The company’s autologous CAR T therapy, Ori-C101, is entering a registration-focused phase II...

Roche subsidiary Foundation Medicine rebranded Saga Diagnostics’ minimal residual disease test as FoundationOne MRD after acquiring Saga for $595 million earlier in 2026. The updated branding...

A new study identified GPR84 as a driver of lung inflammation through PANoptosome activation in the context of influenza A virus infection. Researchers mapped a mechanistic chain linking the...

A Dutch implementation study presented at the European Society of Human Genetics meeting reported that long-read genome sequencing as a first-tier test improved interpretation and reduced...

Summit Therapeutics pulled plans for a $500 million secondary share offering day after announcing it, citing market conditions. The company’s move followed a period of investor scrutiny around...

Life Biosciences said it has treated the first participant in a gene therapy trial designed to partially reprogram aged cells by turning on three genes. The study targets glaucoma, aiming to...

The FDA approved an adjuvant combination of pembrolizumab and belzutifan for adults with high-risk clear cell renal cell carcinoma after surgery. The decision follows translational work from...

Amgen is pushing back against FDA concerns that could remove Tavneos (avacopan) from the market, according to reporting on the company’s request for an independent review. The dispute centers on...

Parabilis Medicines’ Nasdaq debut continued the biotech IPO rebound after the company raised $670 million, following other mega-listings that have restored public-market momentum. The reporting...

Researchers in Turin used residual fecal immunochemical tests (FIT) to probe how the gut microbiome maps onto colorectal cancer risk, leveraging large population-based case-control data across the...

A prenatal diagnostics approach called non-invasive fetal sequencing (NIFS) was presented as matching the accuracy of invasive genetic screening methods while reducing safety risks and cost. The...

Northwestern Medicine researchers reported a safety concern linked to GLP-1 receptor agonists: increased incidence of fainting and dizziness events consistent with hypotensive effects. The work...

A Nature Communications study reported results from a human trial testing deliberate colonization with a non-toxigenic Clostridioides difficile strain. Led by Hensen, Harmanus, Verbeek-Menken and...

SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines. The financing was led by Vida Ventures and includes investors such as ARK Invest,...

Leica Biosystems expanded efforts to commercialize AI-driven oncology pathology tools via the Aperio AI Store by partnering with DiaDeep, a Lyon-based medical AI company. The reseller deal makes...

Amgen escalated its fight over FDA scrutiny of Tavneos (avacopan) by asking for an independent review, according to reporting on the company’s dispute. The request follows FDA concerns tied to...